Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Revenue (2016 - 2025)

Historic Revenue for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $60000.0.

  • Guided Therapeutics' Revenue changed N/A to $60000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $178000.0, marking a year-over-year increase of 36842.11%. This contributed to the annual value of $7000.0 for FY2024, which is 9285.71% down from last year.
  • As of Q3 2025, Guided Therapeutics' Revenue stood at $60000.0.
  • Guided Therapeutics' 5-year Revenue high stood at $117000.0 for Q2 2025, and its period low was $1000.0 during Q4 2024.
  • For the 5-year period, Guided Therapeutics' Revenue averaged around $28923.1, with its median value being $19000.0 (2021).
  • Per our database at Business Quant, Guided Therapeutics' Revenue soared by 78000.0% in 2023 and then plummeted by 9687.5% in 2024.
  • Guided Therapeutics' Revenue (Quarter) stood at $60000.0 in 2021, then crashed by 95.0% to $3000.0 in 2022, then soared by 966.67% to $32000.0 in 2023, then crashed by 96.88% to $1000.0 in 2024, then skyrocketed by 5900.0% to $60000.0 in 2025.
  • Its last three reported values are $60000.0 in Q3 2025, $117000.0 for Q2 2025, and $1000.0 during Q4 2024.